Generic fertility drug could cut IVF costs without sacrificing success

NCT ID NCT06023602

Recruiting now Disease control Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares a generic version of the drug cetrorelix acetate to the original brand in women undergoing IVF. The goal is to see if the generic works just as well at preventing early ovulation and improving live birth rates. Over 1,300 women will participate, and the results could make fertility treatment more affordable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cetrorelix acetate (generic and reference)
What this could lead to: If successful, this could provide a more affordable option for ovarian stimulation during IVF, potentially increasing access to fertility treatment.
What could go wrong: This is a non-inferiority trial, so the generic may be slightly less effective. Results may not apply to all infertility cases, and individual responses to IVF vary widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFERTILITY

Contacts and locations

Locations

He Cai
RECRUITING

Xi'an, None Selected, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.